Hormone therapy for epithelial ovarian cancer

Current Opinion in Oncology

Volumn 20, Issue 5, 2008, Pages 548-553

  Langdon, Simon P ^a   Smyth, John F ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Aromatase inhibitors; Letrozole; Oestrogen receptor; Ovarian cancer; Tamoxifen

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUTAMIDE; GOSERELIN; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MOLECULAR MARKER; MYC PROTEIN; PERTUZUMAB; PLASMINOGEN ACTIVATOR UROKINASE; PROTEIN BIGH3; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; TAMOXIFEN; TOPOISOMERASE II ALPHA; TREFOIL FACTOR 1; TREFOIL FACTOR 3; TREFOIL PEPTIDE; TRIPTORELIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PROTEIN 1; UBIQUITIN CONJUGATING ENZYME E2C; UNCLASSIFIED DRUG; VIMENTIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PATIENT; CLINICAL TRIAL; COHORT ANALYSIS; GENE EXPRESSION; HORMONE RESPONSE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; FEMALE; NEOPLASM; OVARY TUMOR;

ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 59649112608     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283063912     Document Type: Review

References (27)

1. Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007; 13:3617-3622. The first study using a biomarker (ERα) to help in selecting a patient subgroup for treatment with antioestrogen therapy. Within the study, the highest levels of ERa expression were associated with the highest percentage of responders. Other biomarkers associated with response were also identified.
2. Tchekmedyian NS, Liem AK, Quan ET, et al. Aromatase inhibitor therapy for estrogen receptor positive ovarian cancer. J Clin Oncol 2006; 24:15038 [ASCO Annu Meeting Proc Abs].
3. Kavanagh JJ, Hu W, Fu S, et al. Antitumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors. J Clin Oncol 2007; 25:5582 [ASCO Annu Meeting Proc Abs]. The study demonstrates activity of letrozole in low malignant potential or low-grade serous ovarian tumors.
4. Verma S, Alhayki M, Le T, et al. Phase II study of exemestane (E) in refractory ovarian cancer. J Clin Oncol 2006; 24:5026 [ASCO Annu Meeting Proc Abs].
5. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer. Clin Cancer Res 2002; 8:2233-2239.
6. Papadimitriou CA, Markaki S, Siapkaris J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004; 66:112-117.
7. Swerdlow AJ, Jones ME, and the British Tamoxifen Second Cancer Study Group. Ovarian cancer risk in premonopausal and perimenopausal women treated with tamoxifen: a case-control study. Brit J Cancer 2007; 96:850-855. The study has demonstrated that tamoxifen treatment is not associated with increased risk of ovarian cancer.
8. Krasner C. Aromatase inhibitors in gynaecologic cancer. J Steroid Biochem Mol Biol 2007; 106:76-80.
9. Zheng H, Kavanagh JJ, Hu W, et al. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 2007; 17:325-338.
10. Li YF, Hu W, Fu SQ, et al. Aromatase inhibitors in ovarian cancer; is there a role? Int J Gynecol Cancer 2007 [Epub ahead of print].
11. O'Donnell AJ, MacLeod KG, Burns DJ, et al. Estrogen receptor alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Rel Cancer 2005; 12:851-866.
12. Walker G, MacLeod K, Williams ARW, et al. Insulin like growth factor binding proteins IGFBP3, IGFBP4 and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 2007; 13:1438-1444. The study has identified several IGFBP family members, which are oestrogen-regulated in ovarian cancer models. In primary ovarian cancers, increased expression of IGFBP4 and reduced expression of IGFBP3 and IGFBP5 are associated with letrozole response.
13. Walker G, MacLeod K, Williams ARW, et al. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 2007; 106:461-468. The study has identified a series of genes, which are both oestrogen-regulated and are associated with letrozole outcome in ovarian cancer.
14. Tokunaga H, Akahira J, Suzuki T, et al. Ovarian epithelial carcinoma with estrogen-producing stroma. Pathol Int 2007; 57:285-290.
15. Beral V, Bull D, Green J, et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369:1703-1710. The study has demonstrated that oestrogen in the form of HRT causes an increased risk of ovarian cancer when given to postmenopausal women.
16. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives; collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008; 371: 303-314.
17. Chan KKL, Wei N, Liu SS, et al. Estrogen receptor subtypes in ovarian cancer. Obstet Gynecol 2008; 111:144-151. The study has demonstrated that ERβ has properties consistent with a growth suppressor. Expression is higher in normal ovary and in early stage disease and is associated with improved survival.
18. Treeck O, Pfeiler G, Mitter D, et al. Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007; 193:421-433. The in-vitro investigation provides evidence of a growth suppressive role for ERβ in ovarian cancer cells.
19. Sasaki H, Hayakawa J, Terai Y, et al. Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines. Oncogene 2008; 27:2737-2745.
20. Suga S, Kato K, Ohgami T, et al. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynaecologic cancer. Gynecol Oncol 2007; 105:341-350.
21. Mullen P, Cameron D, Hasmann M, et al. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talkwith estrogen receptorsignalling. Mol Cancer Ther2007; 6:93-100. The study using in-vitro cell lines provides evidence of cross talk between oestrogen and HER2 signalling in ovarian cancer cells.
22. Wagner U, Du Bois A, Pfisterer J, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy: a phase II trial of the AGO ovarian cancer study group (AGO-OVARE 2.6). Gynecol Oncol 2007; 105:132-137.
23. Krasner D, Debernado RL, Findley M; et al. Phase II trial of anastrazole in combination with gefitinib in women with asympomatic mullerian cancer. J Clin Oncol 2005; 23:5063 [ASCO Annu Meeting Proc Abst].
24. Levine D, Park K, Juretzka M, et al. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007; 110:2448-2456.
25. Schildkraut JM, Murphy SK, Palmieri RT, et al. Trinucleotide repeat poly-morphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:473-480. The study identified a polymorphism within the androgen receptor linked with an increased risk of ovarian cancer in African-American women.
26. Tworoger SS, Lee I-M, Buiring JE, et al. Plasma androgen concentrations and risk of incident ovarian cancer. Am J Epidemiol 2007; 167:211-218.
27. Fister S, Gunthert AR, Emons G, et al. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 2007; 67:1750-1756. The study demonstrated that GnRH II antagonists can produce apoptosis and may have therapeutic potential in ovarian cancer models.